J. Fredriksson
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Economic and Financial Impacts of Cancer, Cancer survivorship and care
Most-Cited Works
- → Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study(2021)67 cited
- → Flexible care in breast cancer(2021)25 cited
- → Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms(2020)17 cited
- → 165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study(2020)10 cited
- → Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.(2021)7 cited
- → 80O Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+ eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study(2020)3 cited
- → Anti-cancer resource use in the initial management of advanced HER2+ breast cancer: An interim analysis of the UK ESTHER study(2018)